Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

1,886JPY
23 Jul 2014
Price Change (% chg)

¥-0 (-0.03%)
Prev Close
¥1,886
Open
¥1,892
Day's High
¥1,897
Day's Low
¥1,877
Volume
1,351,100
Avg. Vol
2,099,595
52-wk High
¥2,007
52-wk Low
¥1,581

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company has two business segments. The Daiichi Sankyo Group segment is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and... (more)

Overall

Beta: 0.71
Market Cap (Mil.): ¥1,337,550.00
Shares Outstanding (Mil.): 709.01
Dividend: 30.00
Yield (%): 3.18

Financials

  4568.T Industry Sector
P/E (TTM): 21.83 35.48 35.85
EPS (TTM): 86.41 -- --
ROI: 4.11 18.97 18.25
ROE: 6.46 19.75 19.12
Search Stocks

Update-Moody's affirms Daiichi Sankyo's A1 rating; outlook stable

For the full text of this story please click the following link:

02 Jun 2014

Targeted Plexxikon drug helps ease pain from rare joint disease

CHICAGO - An experimental cancer drug being developed by Plexxikon, a unit of Daiichi Sankyo, appears to ease pain and swelling in patients with a rare joint disease caused by a genetic mutation, researchers said on Wednesday.

14 May 2014

Targeted Plexxikon drug helps ease pain from rare joint disease

CHICAGO, May 14 - An experimental cancer drug being developed by Plexxikon, a unit of Daiichi Sankyo, appears to ease pain and swelling in patients with a rare joint disease caused by a genetic mutation, researchers said on Wednesday.

14 May 2014

INDIA PRESS-Daiichi Sankyo contests Andhra Pradesh High Court fiat on Ranbaxy deal-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

11 May 2014

India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats

TOKYO/MUMBAI - India's Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co , and got Ranbaxy India-made drugs barred from the United States. | Video

07 Apr 2014

UPDATE 4-India's Sun Pharma to buy struggling Ranbaxy for $3.2 bln as Daiichi Sankyo retreats

* Investors to get 0.8 Sun Pharma share per Ranbaxy share

07 Apr 2014

Nikkei falls to 1-week low, SoftBank dives on selloff in U.S. tech stocks

* SoftBank dives in wake of selloff in U.S. tech stocks * Daiichi Sankyo soars after Sun Pharma buys Indian unit Ranbaxy * U.S. jobs data positive but overshadowed by Wall Street slide By Ayai Tomisawa TOKYO, April 7 - Japan's Nikkei share average tumbled to a one-week low on Monday morning after a slide on Wall Street overshadowed encouraging U.S. jobs data, and index heavyweight SoftBank Corp dived in the wake of a sell-off in U.S. tech names. Traders said SoftBa

06 Apr 2014

Daiichi Sankyo says Sun Pharma to buy Indian unit Ranbaxy

TOKYO, April 7 - Japan's Daiichi Sankyo Co Ltd said on Monday Sun Pharmaceutical Industries Ltd will buy its Indian unit Ranbaxy Laboratories Ltd , creating the world's fifth-largest speciality generics company.

06 Apr 2014

Daiichi Sankyo pledges bold action on Ranbaxy production problems

TOKYO - Japan's Daiichi Sankyo Co Ltd said it would step up support of Indian drugmaking arm Ranbaxy Laboratories Ltd and send personnel to help resolve problems at a factory that U.S. regulators have banned from supplying pharmaceutical ingredients.

31 Jan 2014

Daiichi Sankyo pledges bold action on Ranbaxy production problems

TOKYO, Jan 31 - Japan's Daiichi Sankyo Co Ltd said it would step up support of Indian drugmaking arm Ranbaxy Laboratories Ltd and send personnel to help resolve problems at a factory that U.S. regulators have banned from supplying pharmaceutical ingredients.

31 Jan 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks